Related Experiment Video

Updated: May 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?

Paul A Gurbel1, Matthew T Roe, Joseph A Jakubowski

  • 1Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W. Belvedere Ave, Baltimore, MD 21215, USA. PGURBEL@LIFEBRIDGEHEALTH.ORG

Thrombosis and Haemostasis
|May 26, 2012
PubMed

Insights

High platelet reactivity to ADP (HPR) after clopidogrel treatment increases ischemic event risk in PCI patients. Further research is needed to understand platelet function testing

Area of Science:

  • Cardiology
  • Pharmacogenomics
  • Clinical Investigations

Background:

  • High platelet reactivity (HPR) to adenosine diphosphate (ADP) is a known risk factor for ischemic events and stent thrombosis in percutaneous coronary intervention (PCI) patients on clopidogrel.
  • Genetic variations, such as CYP 2C19 loss-of-function (LoF) alleles, impact clopidogrel's effectiveness by affecting its absorption and metabolism, potentially increasing thrombotic risk.

Purpose of the Study:

  • To investigate the utility of platelet function testing in predicting outcomes for patients with stable coronary artery disease and medically managed acute coronary syndromes.
  • To assess the longitudinal relationship between platelet function and ischemic event occurrence.
  • To examine the association between on-treatment platelet reactivity, bleeding, and ischemic events in a large-scale antiplatelet therapy trial.

Main Methods:

  • Translational platelet function investigations in PCI-treated populations.
  • Analysis of single nucleotide polymorphisms (SNPs) related to clopidogrel metabolism.
  • Longitudinal assessment of platelet function over time.
  • Evaluation of large phase-III antiplatelet therapy trial data.

Main Results:

  • High platelet reactivity to ADP (HPR) is a significant risk factor for ischemic events and stent thrombosis in PCI patients treated with clopidogrel.
  • CYP 2C19 loss-of-function (LoF) allele carriage is linked to increased thrombotic risk in PCI populations.
  • Current data is insufficient regarding the predictive value of platelet function testing in stable coronary artery disease and medically managed acute coronary syndromes.

Conclusions:

  • Further research is essential to clarify the role of platelet function testing across the spectrum of symptomatic coronary artery disease.
  • The predictive value of platelet function testing in diverse patient populations and over time requires further investigation.
  • Large-scale studies are needed to fully elucidate the relationship between platelet reactivity, clinical outcomes, and bleeding risk.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...